KELNOR 1/35 Rx
Generic Name and Formulations:
Ethynodiol diacetate 1mg, ethinyl estradiol 35mcg, 21 tabs; inert (7 tabs).
Indications for KELNOR 1/35:
1 tab daily for 28 days; repeat.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic adenoma or carcinoma. Pregnancy (Cat.X).
Smokers over 35 years of age: not recommended. Uncontrolled hypertension. Hypertriglyceridemia. Discontinue if jaundice, visual disturbances, migraine or other severe headaches occur. Do regular complete physical exams. May need barrier contraception with Sunday starts or postpartum use (see literature). Nursing mothers: not recommended.
Antagonized by hepatic enzyme inducing drugs (eg, rifampin, griseofulvin, St. John's wort), possibly others. May affect measurement of sex hormone-binding globulin levels.
Progestin + estrogen.
Hypertension, nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, chloasma, mastodynia, headache, intolerance to contact lenses. Increased risk of gallbladder disease, thromboembolic disorders.
- The Vitamin D Debate: Conundrums and Complexities, Part 2
- A Rare Case of Ketoacidosis in a Non-Diabetic Patient: What's the Cause?
- Clinicians Think Rare Disease But Clinical Clues Lead to Something More Disturbing
- CDC Warns of Drug-Resistant 'Superbug' in Multiple U.S. Cities
- Drug Used to Reduce Mortality After MI Discontinued, Generic in Shortage
- Preventing - and Planning for - the Next Influenza Pandemic
- Long-term Testosterone Replacement Ups Risk of Cardiovascular Events, Death in HIV+ Men
- Less Treatment Failures Seen With Empiric Cephalexin in Pediatric UTI
- Some Pediatric Cellulitis Successfully Treated at Home, Study Suggests
- Increased Mortality With Tigecycline as Adjunct Tx for Severe CDAD